PDCI presented a case study on the proposed amendments to the PMPRB regulations in Canada at the 2019 CAPT Conference held by the Canadian Association for Population Therapeutics. The objective of this policy analysis was to estimate the impact of the proposed PMPRB amendments on orphan drug prices. Review our poster ...
In July 2019, CADTH announced a new round of public consultations on its Pharmaceutical Review Programs. CADTH’s proposed changes would affect how it manages, reviews and reconsiders information submitted by pharmaceutical manufacturers through its Common Drug Review. Stakeholders were invited to submit feedback on three consultations: Proposal to Enhance ...
REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ...
PDCI is very pleased to welcome Waleed Adebayo to the PDCI Team as Assistant, Pricing Data Research, effective September 3, 2019. Waleed holds a Bachelor of Economics from Carleton where he is also completing a BSc in Statistics (expected April 2020). He has experience doing data research both at Statistics Canada ...
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. CADTH has extended the ...
PDF Download: Gene Therapy Pathway
PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ...
The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission....
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity ...
PMPRB and Health Canada held two technical briefings on the soon-to-be published final amendments to the Patented Medicines Regulations (PMR) on August 9th, 2019. This coincided with the pre-release of the final regulatory text and an updated Regulatory Impact Analysis Statement (RIAS). Publication in Canada Gazette II is expected August ...